Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reaw...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
SallyC
SallyC Aug. 5 at 8:03 AM
$ABUS $ABUS OHH COME ON ABUS!!! Treat your investors right!!! You can tell us when is your next Earnings Report!!! We are not children!! Stop acting like this or we will really lose confidence in you!! Tell us NOW!!!!!!
0 · Reply
SallyC
SallyC Aug. 5 at 7:59 AM
$ABUS OHH COME ON ABUS!!! Treat your investors right!!! You can tell us when is your next Earnings Report!!! We are not children!! Stop acting like this or we will really lose confidence in you!! Tell us NOW!!!!!!
0 · Reply
Mountainmannn
Mountainmannn Aug. 4 at 7:41 PM
$ABUS I'd love to see $JNJ come in here buy us for 11 billion in stock...
3 · Reply
Grtgooglymoogly
Grtgooglymoogly Aug. 4 at 3:46 PM
$ABUS Just hurry up and settle Pfizer/Biontech, before the price goes up. We know you're not gonna take this to a jury. Imagine some of the message board loons that blame Pfizer /vaccines for so many deaths, instead of Covid itself, on a jury. The $2.25 billion for Pfizer and $2.25 billion for biontech ($4.5 billion total) template created by the Moderna settlement could 50? 100? percent higher with a jury. That patented t-mixer video is locked and loaded. (Plenty of infringed samples too I'd assume).
2 · Reply
Buqqets
Buqqets Aug. 4 at 3:07 PM
0 · Reply
sheepmanct
sheepmanct Aug. 4 at 11:31 AM
$ABUS PFE 10Q, page 25, mentions Arbutus. No real information. “In 2023, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech entities alleging that Comirnaty and its manufacture infringe five U.S. patents, and seeking unspecified monetary damages. Additional patent infringement actions between Genevant/Arbutus and Pfizer/BioNTech are ongoing in certain other ex-U.S. jurisdictions.” https://api-gw-prd.stocktwits.com/earnings-api/v1/documents/d4b7ac03-2614-4ba6-b078-8389909c574f/10-Q.pdf
3 · Reply
CapitalismUSA
CapitalismUSA Aug. 3 at 8:51 PM
$ABUS $PFE Pfizer earnings report tomorrow. Time for these crooks to acknowledge their criminal patent infringement theft.
2 · Reply
DocPharm
DocPharm Aug. 3 at 8:50 PM
0 · Reply
Grtgooglymoogly
Grtgooglymoogly Aug. 3 at 8:30 PM
$ABUS Pfizer response letter to Abus letter, new and blocked on Court Listener.🤷‍♂️
1 · Reply
Grtgooglymoogly
Grtgooglymoogly Aug. 3 at 2:19 PM
$ABUS ...when all through the house, not a creature was stirring, not even a mouse
0 · Reply
Latest News on ABUS
Arbutus Biopharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

Arbutus Biopharma Quarterly report: Q1 2026


Arbutus Biopharma Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

Arbutus Biopharma Earnings release: Q1 2026


Arbutus Biopharma granted Fast Track designation for imdusiran

2026-04-15T11:35:22.000Z - 3 months ago

Arbutus Biopharma granted Fast Track designation for imdusiran


Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Arbutus Biopharma Proxy statement: Proxy filing


Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Arbutus Biopharma Proxy statement: Proxy filing


Arbutus Biopharma Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Arbutus Biopharma Earnings release: Q4 2025


Arbutus Biopharma Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Arbutus Biopharma Annual report: Q4 2025


Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

2026-03-04T16:55:47.000Z - 5 months ago

Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

MRNA


Arbutus Biopharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Arbutus Biopharma Earnings release: Q3 2025


Arbutus Biopharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Arbutus Biopharma Quarterly report: Q3 2025


Arbutus Biopharma Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q2 2025


Arbutus Biopharma Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q2 2025


Arbutus Biopharma Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q1 2025


Arbutus Biopharma Earnings release: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q1 2025


Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing


Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing


Arbutus Biopharma Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q4 2024


Arbutus Biopharma Annual report: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Annual report: Q4 2024


Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update


Arbutus Biopharma Transcript: Status Update

Dec 3, 2024, 11:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Status Update


Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference


Arbutus Biopharma Earnings Call Transcript: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings Call Transcript: Q3 2024


Arbutus Biopharma Quarterly report: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Quarterly report: Q3 2024


Arbutus Biopharma Earnings release: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings release: Q3 2024


Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Two Upcoming Investor Conferences


Arbutus Biopharma Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q2 2024


Arbutus Biopharma Quarterly report: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q2 2024


Arbutus Biopharma Earnings release: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q2 2024


Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 2 years ago

Arbutus Distributors Ltd. News Release


Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 2 years ago

Arbutus to Present Imdusiran Data at EASL Congress 2024


Arbutus Biopharma Earnings Call Transcript: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q1 2024


Arbutus Biopharma Quarterly report: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q1 2024


Arbutus Biopharma Earnings release: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q1 2024


Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing


Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing


Arbutus Biopharma Earnings Call Transcript: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q4 2023


Arbutus Biopharma Annual report: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Annual report: Q4 2023


Arbutus Biopharma Earnings release: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings release: Q4 2023


Arbutus Biopharma Slides: Corporate Presentation

Nov 9, 2023, 7:00 AM EST - 2 years ago

Arbutus Biopharma Slides: Corporate Presentation


Arbutus Biopharma Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q3 2023


Arbutus Biopharma Quarterly report: Q3 2023

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Quarterly report: Q3 2023


Arbutus Biopharma Earnings release: Q3 2023

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings release: Q3 2023


SallyC
SallyC Aug. 5 at 8:03 AM
$ABUS $ABUS OHH COME ON ABUS!!! Treat your investors right!!! You can tell us when is your next Earnings Report!!! We are not children!! Stop acting like this or we will really lose confidence in you!! Tell us NOW!!!!!!
0 · Reply
SallyC
SallyC Aug. 5 at 7:59 AM
$ABUS OHH COME ON ABUS!!! Treat your investors right!!! You can tell us when is your next Earnings Report!!! We are not children!! Stop acting like this or we will really lose confidence in you!! Tell us NOW!!!!!!
0 · Reply
Mountainmannn
Mountainmannn Aug. 4 at 7:41 PM
$ABUS I'd love to see $JNJ come in here buy us for 11 billion in stock...
3 · Reply
Grtgooglymoogly
Grtgooglymoogly Aug. 4 at 3:46 PM
$ABUS Just hurry up and settle Pfizer/Biontech, before the price goes up. We know you're not gonna take this to a jury. Imagine some of the message board loons that blame Pfizer /vaccines for so many deaths, instead of Covid itself, on a jury. The $2.25 billion for Pfizer and $2.25 billion for biontech ($4.5 billion total) template created by the Moderna settlement could 50? 100? percent higher with a jury. That patented t-mixer video is locked and loaded. (Plenty of infringed samples too I'd assume).
2 · Reply
Buqqets
Buqqets Aug. 4 at 3:07 PM
0 · Reply
sheepmanct
sheepmanct Aug. 4 at 11:31 AM
$ABUS PFE 10Q, page 25, mentions Arbutus. No real information. “In 2023, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech entities alleging that Comirnaty and its manufacture infringe five U.S. patents, and seeking unspecified monetary damages. Additional patent infringement actions between Genevant/Arbutus and Pfizer/BioNTech are ongoing in certain other ex-U.S. jurisdictions.” https://api-gw-prd.stocktwits.com/earnings-api/v1/documents/d4b7ac03-2614-4ba6-b078-8389909c574f/10-Q.pdf
3 · Reply
CapitalismUSA
CapitalismUSA Aug. 3 at 8:51 PM
$ABUS $PFE Pfizer earnings report tomorrow. Time for these crooks to acknowledge their criminal patent infringement theft.
2 · Reply
DocPharm
DocPharm Aug. 3 at 8:50 PM
0 · Reply
Grtgooglymoogly
Grtgooglymoogly Aug. 3 at 8:30 PM
$ABUS Pfizer response letter to Abus letter, new and blocked on Court Listener.🤷‍♂️
1 · Reply
Grtgooglymoogly
Grtgooglymoogly Aug. 3 at 2:19 PM
$ABUS ...when all through the house, not a creature was stirring, not even a mouse
0 · Reply
hopeful2bright
hopeful2bright Aug. 2 at 8:27 PM
$ABUS It would be nice to know what ABUS has to say about future of HepB and not silence. Why not say what they think and only big institutions to know what’s going on? They must know, otherwise why did they buy so many shares and certainly looks like they‘re holding long. There won’t be any shares to buy on open market so price of stock will only go up. Then say what’s happening? PFE then settles and not only ABUS has money but HepB is huge? So many questions. I’ll hold long.
0 · Reply
Thepatientone
Thepatientone Aug. 2 at 2:28 PM
$ABUS - Overall, I think Arbutus/Genevant came out ahead procedurally. Not because they won every issue, but because: Pfizer narrowed several of its requests. The judge largely rejected broad "discovery about discovery." The judge directed Pfizer to make targeted requests instead of granting broad relief. Arbutus used Pfizer's failure to follow up after the hearing to argue that the motion to compel should now be denied as moot.
1 · Reply
Wonderbread1988
Wonderbread1988 Aug. 2 at 1:42 PM
1 · Reply
Alfalcon
Alfalcon Aug. 1 at 10:21 PM
$ABUS sounds like we may be heading toward 17th century tulip market
0 · Reply
Abus4ever
Abus4ever Aug. 1 at 6:09 PM
$ABUS one mire post.. The 114-year-old Section 1498 law is an archaic relic never designed to shield multi-billion-dollar corporations that pocketed massive private wealth from taxpayer-funded research. Because Pfizer and Moderna commercialized this technology globally to generate over 100 billion dollars in gross revenue, they cannot simply steal intellectual property. Modern federal courts must update this law, stipulating strict compliance steps where manufacturers and the government establish proactive, good-faith licensing frameworks. These necessary administrative steps can be processed concurrently even while a rushed vaccine deployment is already underway. Since these record profits were made possible by the taxpayer and the law, the manufacturers must pay royalties directly out of their own corporate treasuries.
0 · Reply
Abus4ever
Abus4ever Aug. 1 at 5:46 PM
$ABUS as I look deeper the more convinced I am. I see the earnings are on August 5, but the. presentation is on August 13? why the gap or am I wrong? Activist hedge fund Whitefort Capital Management sent an open letter on May 17, 2024, demanding an end to stock dilution and a push for a big pharma partnership. Backing up their demands, Whitefort aggressively increased its stake on April 10, 2026, to 15,794,261 shares, making Arbutus its largest investment holding at 8.00% of the entire company. Simultaneously, Rubric Capital Management boosted its position during the first quarter of 2026 by a massive 320.6% to control 6,634,815 shares, which was officially disclosed to the public on May 15, 2026. This combined wave of massive institutional accumulation hitting the record in May 2026 means these two activist funds alone now own 22,429,076 shares, locking up over 11.3% og the float.
1 · Reply
SpaceCityKid
SpaceCityKid Aug. 1 at 5:09 PM
$ABUS Also from the 7/16 press release, there was one sentence that really stood out, "repurchases may come in the form of a tender offer (including a modified “Dutch Auction” tender offer), open market purchases, privately negotiated transactions, accelerated share repurchases or other means"... This sure doesn't seem like your typical share repurchase announcement.
1 · Reply
Abus4ever
Abus4ever Aug. 1 at 4:26 PM
$ABUS The government handles safety lawsuits since it rushed the clinical protocols, but it is not responsible for Moderna's private commercial profits. Moderna originally tried to get the delivery technology on the cheap before the pandemic, but after failing to negotiate a fair royalty deal with Arbutus, they used the patents anyway. On July 17, 2026, the U.S. government filed a formal response in court explicitly refusing to accept financial liability for Moderna’s actions. Because Moderna pocketed thirty-five billion dollars in revenue from the rollout, the court maintains that the company must pay for its own underlying patent technology rather than shifting that debt to the taxpayer.
1 · Reply
Jdvm
Jdvm Jul. 31 at 5:35 PM
1 · Reply
SpaceCityKid
SpaceCityKid Jul. 31 at 4:39 PM
$ABUS They stated in their 7/16 press release that "any repurchase will not commence until after receipt of the expected dividend from Genevant’s parent in Q3 2026". That payment could happen any day. So there is still a window of opportunity here, but it's rapidly closing.
0 · Reply
punktdot
punktdot Jul. 31 at 4:29 PM
$ABUS Let's look at the facts: 1. The share buyback program comes first. it could actually retire between 19-25% of outstanding shares and, based on yesterdays close, push the stock above $6. 2. The most important case is the Federal Circuit. The decision not only has a massive impact on possible Pfizer/BNTX payments, but also on the additional MRNA payments. It's two eggs in one basket. If the feds decide that government = the entire public, ABUS loses a lot of potential value. 3. All other developments are secondary. Which means short term, the buyback might help push the share price, but the real deal starts 1Q 2027 and a final decision might only come late 2027 or even early 2028. A lot of time for an unsure result.
2 · Reply
mj6534
mj6534 Jul. 31 at 4:16 PM
0 · Reply